Navigation Links
BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea
Date:11/10/2008

CMP Will Purchase at Least 227 HyperQ(TM) Systems During the Term of the

Agreement

TEL AVIV, Israel, November 10 /PRNewswire-FirstCall/ -- BSP (Biological Signal Processing Ltd.) (http://www.bsp.co.il/), an Israeli company that develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease (IHD), announced that it has signed an exclusive distribution agreement with CMP Trading Co., Ltd to distribute HyperQ(TM) Stress System in South Korea.

CMP has undertaken to purchase at least 227 HyperQ(TM) systems through the end of 2011. The number of systems may change subject to the date of receipt of regulatory approval from the Korean Food and Drug Administration, an essential step towards the marketing and use of the system in Korea. BSP estimates that the price per system to CMP will vary from about US$ 15,000 to roughly US$ 20,000, dependent on the system configuration. Accordingly, the total revenues resulting from this agreement are expected to be a minimum of US$ 3,400,000.

Mr. Chan Min Park, President of CMP Trading said, "We are extremely encouraged by the very positive response to the HyperQ technology from medical centers. We believe that BSP's product can change the way ischemic heart diseases are being diagnosed."

"This second distribution agreement consolidates BSP's position in the Asia-Pacific markets. We view Korea as one of the most receptive countries to innovative technologies," said Dr. Amir Beker, BSP's founder and CEO.

Dr. Beker adds, "We are grateful for the ongoing vote of confidence in our HyperQ technology by leading physicians in Asia and the United States. We plan to continue with the installment of our HyperQ system into top medical centers."

This week, BSP is introducing its new version of the HyperQ(TM) System at the 2008 conference of the American Heart Association in New Orleans.

BSP - background

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange.

Contacts:

Dr. Amir Beker, CEO

Dr. Neri Malka, Head of Clinical Marketing

Tel: +1-888-669-1671; +972-3-647-4840


'/>"/>
SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
3. Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography
4. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
5. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
6. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
7. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
10. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
11. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):